ASH News Daily - Sunday, December 11, 2011 - (Page B-16)

ASH NewS DAily Now Recruiting…… A New Clinical Trial for Patients with High-risk Smoldering Multiple Myeloma About Smoldering Multiple Myeloma (SMM) Smoldering multiple myeloma (SMM) is an asymptomatic condition that over time will transition into the malignant disease of multiple myeloma (MM). Study Overview Janssen Research, a unit of Centocor Research and Development, Inc., is conducting a study on SMM. In a global study 50 high-risk SMM subjects will be randomized to study drug and 50 subjects will be randomized to placebo (same drug without active ingredient). The study is double-blind, that is both doctors and patients will not know if the study drug or placebo will be given. The study intends to evaluate and/or follow subjects for 4-5 years. SH recognizes Marie Arturi, co-founder and executive director of the Daniella Maria Arturi Foundation, with the 2011ASH Award for Outstanding Service for her dedication to raising public awareness and increasing research funding for hematologic diseases, including rare disorders such as Diamond-Blackfan anemia. The Society presents this award each year to individuals in both the public and private sectors who have displayed effective “behind-the-scenes” leadership in areas relMarie Arturi evant to the mission of the Society. Mrs. Arturi and her husband, Manny, established the Daniella Maria Arturi Foundation in early 1996 shortly after the death of their daughter, Daniella, who was diagnosed with Diamond-Blackfan anemia. Noting the difficult reality of the very limited information available to A Diamond-Blackfan Anemia Supporter Receives 2011 Outstanding Service Award families caring for children with extraordinarily rare disorders such as Diamond-Blackfan anemia, Mrs. Arturi created the Daniella Maria Arturi Foundation in order to improve the Diamond-Blackfan anemia clinical care environment, advance family and physician access to up-to-date Diamond-Blackfan anemia information, raise public awareness, and support and stimulate research initiatives that would work toward improved treatment options and a cure for Diamond-Blackfan Anemia. Mrs. Arturi has been a dedicated supporter of research on congenital bone marrow failures, and the Daniella Maria Arturi Foundation sponsors an annual meeting on bone marrow failure syndromes. The 2011 Outstanding Service Award will be formally announced prior to the Plenary Scientific Session today at 1:30 p.m. ® Primary Objective The primary objective of the study is to evaluate the 1-year progression-free survival (PFS) rate in patients with smoldering multiple myeloma (MM) with an investigational medication. 2011 Outstanding Abstract Achievement Award Recipients he American Society of Hematology is pleased to recognize the following abstract presenters who received the highest ranking in their categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow. Outstanding Abstract Achievement Award winners receive $500 plus coach-class airfare to San Diego and hotel accommodations for two nights. Undergraduate Student Kathryn Luk Tuesday, December 13: 7:30 a.m., Manchester Grand Hyatt San Diego, Douglas Pavilion D Hemoglobinopathies, excluding Thalassemia: Sickle Cell Disease - New Insights into Pathophysiology Association of Mu Opioid Receptor with Neurogenic Inflammation in Sickle Mic Abstract #895 Medical Student Morgan Jones Monday, December 12: 11:00 a.m., San Diego Convention Center, Room 25 Hematopoietic Stem and Pro- T Major Inclusion Criteria ■ Diagnosis of SMM for < 4 years ■ Diagnosis of high-risk SMM; ■ ECOG Performance score of 0 or 1 genitor Biology: Epigenetic Regulation of Hematopoietic Stem and Progenitor Cells The Trithorax Group Protein Ash1l is an Essential Epigenetic Regulator of Adult Hematopoietic Stem Cell Maintenance Abstract #387 Alison Schram Today: 5:15 p.m., San Diego Convention Center, Ballroom 20D Myeloproliferative Syndromes: Biological Advances I Genetic and Functional Investigation of Germline JAK2 Alleles That Predispose to Myeloproliferative Neoplasms Abstract #124 Resident Physician Christian Braun, MD Today: 5:00 p.m., Manchester Grand Hyatt San Diego, Elizabeth Ballroom DE Gene Therapy and Transfer: Clinical Gene Therapy Efficacy of Gene Therapy for Wiskott-Aldrich-Syndrome Abstract #165 »» ABSTRACTS Page B-20 Study Design 100 patients(1:1) Receive investigational medication as an infusion every 4 weeks Receive placebo as an infusion every 4 weeks About the Investigative Medication The investigational medication is a monoclonal antibody that binds to IL-6. For more information, please email: mbalvers@its.jnj.com or btromp@its.jnj.com SMM-2001-ENG15 Version 1.0, 17JUN2011 

Table of Contents for the Digital Edition of ASH News Daily - Sunday, December 11, 2011

ASH News Daily - Sunday, December 11, 2011

https://www.nxtbookmedia.com